RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company at the following investor conferences:
- The 26th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 8:30 a.m. Eastern Time
- The Oppenheimer 25th Annual Healthcare Conference in New York on Wednesday, December 10, 2014 at 9:45 a.m. Eastern Time
Links to a live audio webcast and replay of the presentations may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: oral inhibitors of plasma kallikrein for hereditary angioedema, including BCX4161 and several second generation compounds; RAPIVABTM (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, and BCX4430, a broad spectrum viral RNA polymerase inhibitor. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910